Screener
BridgeBio Pharma BBIO Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| 2033 Notes, net | 620,087 | — |
| Deferred royalty obligations, net (3) | 879,374 | 855,030 |
| Operating lease liabilities, net of current portion | 14,973 | 3,811 |
| Deferred revenue, net of current portion | 10,424 | 13,080 |
| Other long-term liabilities | 240 | 244 |
| Total liabilities | 3,723,192 | 3,012,606 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (1,018) | (570) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's contract liabilities, non-current?
- BridgeBio Pharma (BBIO) reported contract liabilities, non-current of $10.42M in Q2 2026.
- What does contract liabilities, non-current mean?
- Obligation to transfer goods or services for which payment has been received, expected to be satisfied beyond one year.
Ask your AI about BridgeBio Pharma's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude